(Q36437111)

English

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma (English)

1 reference

Europe PubMed Central

14 August 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tanios Bekaii-Saab

2

object named as

Tanios Bekaii-Saab

1 reference

Europe PubMed Central

14 August 2017

9

object named as

Eric A Collisson

1 reference

Europe PubMed Central

14 August 2017

author name string

Andrew H Ko

1

1 reference

Europe PubMed Central

14 August 2017

Jessica Van Ziffle

3

1 reference

Europe PubMed Central

14 August 2017

Olga M Mirzoeva

4

1 reference

Europe PubMed Central

14 August 2017

Nancy M Joseph

5

1 reference

Europe PubMed Central

14 August 2017

AmirAli Talasaz

6

1 reference

Europe PubMed Central

14 August 2017

Peter Kuhn

7

1 reference

Europe PubMed Central

14 August 2017

Margaret A Tempero

8

1 reference

Europe PubMed Central

14 August 2017

R Kate Kelley

10

1 reference

Europe PubMed Central

14 August 2017

Alan P Venook

11

1 reference

Europe PubMed Central

14 August 2017

Elizabeth Dito

12

1 reference

Europe PubMed Central

14 August 2017

Anna Ong

13

1 reference

Europe PubMed Central

14 August 2017

Sharvina Ziyeh

14

1 reference

Europe PubMed Central

14 August 2017

Ryan Courtin

15

1 reference

Europe PubMed Central

14 August 2017

Regina Linetskaya

16

1 reference

Europe PubMed Central

14 August 2017

Sanaa Tahiri

17

1 reference

Europe PubMed Central

14 August 2017

W Michael Korn

18

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

6 August 2015

1 reference

Europe PubMed Central

14 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

14 August 2017

22

1 reference

Europe PubMed Central

14 August 2017

1

1 reference

Europe PubMed Central

14 August 2017

61-68

1 reference

Europe PubMed Central

14 August 2017

Oncogenic KRAS signalling in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

EGF receptor is required for KRAS-induced pancreatic tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Genetics and biology of pancreatic ductal adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

30 September 2017

SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

28 June 2018

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

21 September 2018

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

21 September 2018

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

21 September 2018

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4703532

21 September 2018

Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26251290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-15-0979

1 reference

Europe PubMed Central

14 August 2017

release_oet6yvcmhrbndb2bf4umyu4uqa

1 reference

https://api.fatcat.wiki/v0/release/oet6yvcmhrbndb2bf4umyu4uqa

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36437111&oldid=1987339843"